German Christopher Paul 4

What Happened
Christopher German, Corporate Controller & Chief Accounting Officer of Rhythm Pharmaceuticals (RYTM), was granted 5,215 restricted stock units (RSUs) on February 11, 2026. The award is reported at an acquisition price of $0.00 (typical for compensation grants); the filing classifies this as a derivative award (transaction code A). Each RSU represents a contingent right to receive one share of common stock upon vesting.

Key Details

• Transaction date: 2026-02-11 (Form filed 2026-02-13)
• Transaction type/code: Grant of RSUs (A = Award/Grant); reported as a derivative acquisition
• Shares granted: 5,215 restricted stock units; reported acquisition price $0.00
• Shares owned after transaction: Not disclosed in the provided filing excerpt
• Footnotes: F1 — each RSU converts to one common share upon vesting; F2 — vesting schedule is 25% on each of Feb 1, 2027, 2028, 2029 and 2030; RSUs have no expiration date
• Timeliness: Filing was submitted two days after the transaction date (within the typical Form 4 reporting window); no late filing flag indicated

Context
RSU grants are a form of equity compensation and do not involve an immediate purchase or sale of shares. These units will convert into company stock only as they vest per the stated schedule; there was no immediate sale or cashless exercise reported. Such awards are common for executives and are more about long-term retention and compensation than an immediate signal of insider bullishness or bearishness.